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Background: It is unknown how sphingolipids arrive at plasma.
Results: Plasma ceramide and sphingomyelin are low in microsomal triglyceride transfer protein (MTP)-deficient humans and
mice. MTP does not play a role in sphingolipid synthesis.
Conclusion:MTP transfers and assists in the secretion of ceramide and sphingomyelin with apoB-containing lipoproteins.
Significance:MTP is a major and a partial determinant of plasma ceramide and sphingomyelin, respectively.
Sphingolipids, a large family of bioactive lipids, are implicated
in stress responses, differentiation, proliferation, apoptosis, and
other physiological processes. Aberrant plasma levels of sphin-
golipids contribute to metabolic disease, atherosclerosis, and
insulin resistance. They are fairly evenly distributed inhighden-
sity and apoB-containing lipoproteins (B-lps). Mechanisms
involved in the transport of sphingolipids to the plasma are
unknown. Here, we investigated the role of microsomal triglyc-
eride transfer protein (MTP), required for B-lp assembly and
secretion, in sphingolipid transport to the plasma. Abetalipo-
proteinemia patients with deleterious mutations in MTP and
absence of B-lps had significantly lower plasma ceramide and
sphingomyelin but normal hexosylceramide, lactosylceramide,
and different sphingosines compared with unaffected controls.
Furthermore, similar differential effects on plasma sphingolip-
ids were seen in liver- and intestine-specific MTP knock-out
(L,I-Mttp/) mice, suggesting that MTP specifically plays a
role in the regulation of plasma ceramide and sphingomyelin.
We hypothesized that MTP deficiency may affect either their
synthesis or secretion. MTP deficiency had no effect on cer-
amide and sphingomyelin synthesis but reduced secretion from
primary hepatocytes and hepatoma cells. Therefore, MTP is
involved in ceramide and sphingomyelin secretion but not in
their synthesis.We also found thatMTP transferred these lipids
between vesicles in vitro. Therefore, we propose that MTP
might regulate plasma ceramide and sphingomyelin levels by
transferring these lipids to B-lps in the liver and intestine and
facilitating their secretion.
Because of their hydrophobicity, lipids are transported in the
aqueous milieu (plasma) of blood associated with proteins (e.g.
albumin) or lipoproteins (1, 2). There are two types of plasma
lipoproteins as follows: apoB-containing lipoproteins (B-lps)4
and apoB-free high density lipoproteins (HDLs). B-lps and
HDLs transport different lipids in the plasma compartment (1).
Triglycerides are transported with B-lps, whereas phospholip-
ids and cholesterol are transported with both B-lps and HDL.
B-lps are assembled in the endoplasmic reticulum (ER) and
Golgi of hepatocytes and enterocytes in a two-step process that
requires microsomal triglyceride transfer protein (MTP) (3, 4).
Kinetic studies suggest that MTP has two lipid transfer sites as
follows: a slowphospholipid transfer site that is hypothesized to
be in the N-terminal domain and a fast bulk lipid (triglyceride,
phospholipid, and cholesterol ester) transfer site in the C-ter-
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minal domain (5). In the first step, MTP physically associates
with apoB to help translocation across the ER membrane and
transfers triglycerides, phospholipids, and cholesterol esters to
nascent apoB to form primordial lipoproteins. In the second
step, primordial lipoproteins fusewith lumenal lipid droplets to
form mature particles. It is possible that MTP may also partic-
ipate in the formation of lumenal lipid droplets and their fusion
with the primordial particles (3, 4).
In humans, MTP deficiency results in abetalipoproteinemia
(ABL), which is a rare autosomal recessive disorder with an
estimated frequency of 1 in 1,000,000 characterized by the
absence of plasma B-lps, fat-soluble vitamin deficiency, stunted
growth, and acanthocytosis (6). ABL patients have low plasma
levels of glycerolipids (triglycerides and phospholipids) and
cholesterol, but the concentrations of sphingolipids in their
plasma are unknown.
Germ lineMTP ablation inmice is embryonic lethal (7, 8). In
postnatal animals, however, liver-specific ablation of MTP
reduces plasma cholesterol and triglycerides by 60–80% and
increases their hepatic concentrations (8–10). Intestinal MTP
gene deletion in mice also reduces (40–50%) plasma triglyc-
erides and cholesterol levels and enhances triglyceride and free
fatty acid accumulation in the intestine (11–13). However, the
effect of tissue-specific MTP deficiency on plasma and tissue
sphingolipids in mice is unknown.
Sphingolipids include hundreds of distinctmolecular species
consisting of the common 18-carbon amino-alcohol backbone,
sphingosine. Cellular sphingolipids are biologically active in
signaling, differentiation, apoptosis, stress responses, inflam-
mation, atherosclerosis, and lipoprotein metabolism (14–16).
Different species of sphingolipids carry out distinct functions.
Ceramides act as tumor suppressors by augmenting apoptosis,
autophagy, and cell cycle arrest (17). Their accumulation in the
muscle, adipose tissue, and heart increases insulin resistance,
inflammation, and atherosclerosis (16, 18). In contrast to cer-
amides, glucosylceramides support cell proliferation and differ-
entiation, and the ablation of genes involved in their synthesis
results in embryonic lethality (19). In ob/ob mice, glucosylcer-
amides are increased, and inhibition of their synthesis improves
glucose homeostasis, adipocyte function, and insulin sensitivity
(19). Atherosclerotic plaques contain large amounts of lacto-
sylceramide,which appear to stimulate smoothmuscle cell pro-
liferation and increase expression of adhesionmolecules in vas-
cular endothelial cells (20). Sphingomyelins are concentrated in
lipid rafts, and these membrane microdomains perform spe-
cialized functions such as cell signaling, lipid and protein sort-
ing, cholesterol efflux, and an inflammatory response (21, 22).
De novo sphingolipid synthesis begins in the ER with the
condensation of serine and palmitoyl-CoA to form 3-ketodihy-
drosphingosine followed by its reduction to dihydrosphin-
gosine.Dihydrosphingosine is acylated to dihydroceramide and
reduced to ceramide. Ceramides are then transported to the
Golgi via ceramide transfer protein, four-phosphate adaptor
protein 2 (FAPP2), or transport vesicles for the synthesis of
sphingomyelin, hexosylceramide, lactosylceramide, and other
complex sphingolipids. In the salvage pathway, sphingomyelin
is hydrolyzed to sphingosine and transported to the ER for cer-
amide synthesis. Ceramide can also be generated on the plasma
membrane by sphingomyelinases.
Although intracellular transport of sphingolipids is widely
studied, mechanisms of their transport to the plasma are
unknown. Sphingolipids are present in plasma associated with
both B-lps and HDLs in nearly equal concentrations (23–25).
Sphingosines and their 1-phosphates are associated with albu-
min and HDL (26). Higher levels of plasma sphingolipids are
associatedwith various pathologies. Total plasma ceramide lev-
els are increased in cardiovascular disease (27), type 2 diabetes
(28, 29), obesity (28), and insulin resistance (16). Plasma sphin-
gomyelin levels are higher in hypercholesterolemia and
increase the risk for coronary artery disease (30, 31). Thus,
there is a need to know the origin and mechanisms involved in
the regulation of plasma sphingolipids.
Studies in rat primary hepatocytes have suggested that pal-
mitic acid treatment increases cellular and secreted ceramide
(32, 33). However, secretion of sphingomyelin was equivocal.
Secreted ceramide was mainly associated with VLDL (32). Pal-
mitic acid also increased cellularMTP andABCA1 (33). There-
fore, it has been speculated that MTP and ABCA1might play a
role in ceramide secretion (33). Here, we explored the role of
MTP and B-lps in the transport of various sphingolipids from
the liver and intestine to the plasma.
Experimental Procedures
Materials—[3H]Triolein (22 Ci/mmol), [3H]sphingomyelin
(60 Ci/mmol), [3H]dihydrosphingosine (60 Ci/mmol), and
[14C]ceramide (50mCi/mmol) were purchased fromAmerican
Radiolabeled Chemicals, Inc. NBD-ceramide (catalog no. 6224)
was purchased from Setareh Biotech, and NBD-sphingomyelin
(catalog no. 229573) was from Avanti Polar Lipids.
Human plasma samples from heterozygous (HE, n 4) and
homozygous (HO, n  9) ABL subjects were collected at the
University of Pennsylvania, University of Modena and Reggio
(Emilia, Italy), The Robarts Research Institute (Canada), and
theWashington University School ofMedicine (St. Louis) after
obtaining approval from the universities’ institutional review
boards and consent from subjects and/or parents. Frozen sam-
ples were shipped to the State University of New York Down-
state Medical Center where different analyses were performed.
Additionally, appropriate aliquots of these samples were
shipped from the State University of New York Downstate to
the Lipidomics Shared Resource at the Medical University of
South Carolina for sphingolipid analyses using LC-MS/MS as
described previously (24).
Animals—Chow fed, male, 10-week-old mice on a C57BL/6J
background were used in these studies. ERT2-villin-Cre;Mttp
(Mttpf/f) mice have been described previously (12, 34). These
mice were generated by breeding mice that carry floxed Mttp
gene with ERT2-villin-Cre mice. To generate liver- and intes-
tine-specific MTP-ablated (L,I-Mttp/) mice, 8-week-old
Mttpf/f mice were injected once intravenously with 109 pfu of
either AAV-TBG-Luc (control) or AAV-TBG-Cre viruses (to
ablate hepatic floxed genes) in 100 l of sterile PBS. Addition-
ally, mice injected with AAV-TBG-Luc were injected intraperi-
toneally with 200 l of corn oil for 3 alternate days to serve as
controls. Mice injected with AAV-TBG-Cre were injected with
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0.5 mg of tamoxifen (induces Cre-recombinase expression in
the intestine to ablate floxed genes) in 200 l of corn oil for 3
alternate days to obtain L,I-Mttp/ mice. Plasma and tissues
were harvested 7 days after the last tamoxifen injection. All
experiments were approved by the Institutional Care and Use
Committee at StateUniversity ofNewYorkDownstateMedical
Center.
MTP Lipid Transfer Assays—MTP lipid transfer assays were
performed as described before (35–37). Donor phosphatidyl-
choline vesicles were prepared by sonicating 1.8 mol of phos-
phatidylcholine, 135 nmol of cardiolipin, and 1 Ci of radiola-
beled [3H]triolein, [14C]ceramide, or [3H]sphingomyelin in 4.5
ml of buffer II (15 mM Tris, 40 mM NaCl, 1 mM EDTA, 0.02%
NaN3, pH 7.4) for 20 min. Acceptor vesicles were prepared by
sonicating 10.8 mol of phosphatidylcholine and 21.6 nmol of
triolein in 4.5 ml of buffer II for 40 min. Donor and acceptor
vesicles were centrifuged in Beckman Coulter ultracentrifuge
for 60 min at 50,000 rpm and 10 °C. The top 4 ml were trans-
ferred to a different tube. For blank and totals, 50 l of donor
and 50 l of acceptor vesicles were incubated with 200 l of
BSA stock (10 mg of fatty acid-free BSA/ml buffer II). To mea-
sure MTP activity, 50 l of donor vesicles, 50 l of acceptor
vesicles, and 200 l of BSA stock were incubated with purified
MTP or tissue homogenates. After 1 h, 200 l of DE52 (1:1 v/v
suspension in buffer containing 15mMTris, 1mMEDTA, 0.02%
NaN3, pH 7.4) was added in blank and MTP samples (totals
received only the above buffer), mixed for 5 min by rotation,
and centrifuged for 10min at 12,000 g and 4 °C. To determine
the amounts of radiolabeled lipids transferred to acceptor ves-
icles, supernatants (200l) were added to 5ml of a scintillation
mixture and counted in a scintillation counter. Amounts of
radiolabel transferred to acceptor vesicles were quantified and
expressed as % transfer/h.
Todetermine IC50 values, donor vesicles containing different
radiolabeled lipids were incubated with 1 g of purified MTP
with indicated concentrations of lomitapide. After 1 h, DE52
was added to precipitate donor vesicles. Amounts of radioac-
tivity transferred to acceptor vesicles were quantified. Non-lin-
ear regression analysis (Graphpad Prism) was used to calculate
IC50 values.
Cell Culture Studies—To study the effect of MTP inhibitor
on sphingolipid synthesis, Huh-7 cells were incubated with
fumonisin B1 (50 M) or lomitapide (500 nM) for 2 h, washed,
and then incubated with [3H]dihydrosphingosine (0.5Ci) and
15Munlabeled dihydrosphingosine for 1 or 3 h in the presence
and absence of different inhibitors. Lipids from cells were
extractedwith 100l of isopropyl alcohol and separated on thin
layer silica plates (catalog no. 44931, Analtech, Inc.) using a
CHCl3/CH3OH/C6H5CH3/NH4OH/H2O (40:40:20:0.4:1.6, ra-
tios by volume) solvent system.
To determine whether MTP inhibition affects sphingolipid
secretion, cells were incubated with fumonisin B1 (50 M) or
lomitapide (500 nM) and [3H]dihydrosphingosine (0.5 Ci) for
16 h. Lipids from media were extracted with CHCl3/CH3OH
(2:1, v/v) (38). Lipids were evaporated, dissolved in 100 l of
isopropyl alcohol, and separated by TLC as described above.
Ceramide Synthesis—Liver or intestinal homogenates (250
g of protein) fromwild-type and L,I-Mttp/mice were incu-
bated with [3H]dihydrosphingosine (0.05 Ci), dihydrosphin-
gosine (15 M), fatty acid-free BSA (20 M), and different fatty
acyl-CoAs (50 M) in the presence or absence of fumonisin B1
(50 M) or lomitapide (500 nM) in a total volume of 200 l
reaction for 30 min at 37 °C. The reaction was stopped by add-
ing 200 l of CHCl3/CH3OH (2:1, v/v). Lipids were extracted
and subjected to TLC.
Sphingomyelin Synthesis—Liver tissues from wild-type and
L,I-Mttp/mice were homogenized in a buffer containing 50
mMTris-HCl, 1mMEDTA, 5% sucrose, pH7.4, and amixture of
protease inhibitors. The homogenate was centrifuged in a
tabletop centrifuge 5415D (Eppendorf) at 5,000 rpm for 10min
at 4 °C. The supernatant (250 g of protein) was added to assay
buffer containing 50mMTris-HCl, pH7.4, 25mMKCl, C6-NBD
ceramide (3.3 g/ml), and phosphatidylcholine (100 g/ml) in
a total volume of 200l reaction and incubated for 2 h at 37 °C.
The reaction was stopped by adding 200 l of CHCl3/CH3OH
(2:1, v/v). Lipids were extracted and subjected to TLC.
Enterocytes fromwild-type and L,I-Mttp/were isolated as
described previously (39). Enterocytes or Huh-7 cells were
incubated with C6-NBD ceramide (3.3 g/ml) and phosphati-
dylcholine (100g/ml) in the presence or absence of lomitapide
(500 nm), D609 (500 M), an inhibitor of sphingomyelin syn-
thesis, for 2 h. Lipids were extracted from cells with isopropyl
alcohol and separated by TLC.
Quantification of Lipids and Apolipoproteins—Kits were
used to measure triglycerides (Thermo Fisher Scientific, cata-
log no. TR22421), phospholipids (Wako Diagnostics, catalog
no. 433-36201), and cholesterol (Thermo Fisher Scientific, cat-
alog no. TR13421) in plasma, liver, and intestinal samples
according to the manufacturer’s instructions. Sphingolipids
were quantified by LC-MS/MS as described before (24).
Human apoB and apoAI were quantified by ELISA (40, 41).
Quantification of Sphingolipids—Plasma (100 l) from
homozygous (ABL, n  9) or heterozygous (HE ABL, n  4)
ABL subjects, as well as L,I-Mttp/ (n 3) and Mttpf/f (n 4)
mice (150 l), were used for the quantification of different spe-
cies of ceramide, sphingomyelins, hexosylceramide, and lacto-
sylceramide using HPLC-MS/MS (24). Amounts of different
sphingolipid species were combined to obtain total plasma lev-
els. Two milligrams of liver or intestinal tissue homogenates
were used to quantify intracellular sphingolipids. Feces col-
lected over a 48-h period were dehydrated and crushed with a
mortar and pestle. Sphingolipids were measured in 1 g of dried
feces.
Statistics—Comparisons between wild-type and different
knock-out mouse models were made by Student’s t test. Com-
parisons among HE ABL and HO ABL subjects were evaluated
using Student’s t test using Graphpad Prism. Significance
among different treatments in Figs. 4–6 was determined by
one-way analysis of variance followed by the Dunnett’s test
between untreated cells or homogenates and each condition.
Results
Plasma Ceramide and Sphingomyelin Concentrations Are
Significantly Reduced in ABL Patients—Wemeasured the con-
centrations of the traditional plasma lipids and apolipopro-
teins, as well as those of multiple sphingolipid classes, in the
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plasma of ABL subjects and compared them with their unaf-
fected HE ABL siblings and parents. ABL subjects had signifi-
cantly lower total plasma triglyceride, cholesterol, phospho-
lipid, apoB, and apoA1 (Fig. 1, A–D, and supplemental Table
S1). ABL subjects also had significantly lower total plasma cer-
amide (82%, Fig. 1E) and sphingomyelin (41%, Fig. 1I). All
other sphingolipids were not significantly different from HE
ABL (Fig. 1, F–H, and J–M, and supplemental Table S1). All
ceramide species were lower in ABL compared with HE ABL;
however, hexosylceramide, lactosylceramide, and sphingosine
species were similar in these two groups (supplemental Tables
S2– 4). Except for C18, C24:1, C26, and C26:1, all sphingomy-
elin species were lower in ABL (supplemental Table S5). Thus,
ABL subjects exhibited significantly lower plasma concentra-
tions of ceramide and sphingomyelin, but the plasma concen-
trations of other quantified sphingolipids were not reduced.
Plasma Ceramide and Sphingomyelin Levels Are Significantly
Lower in Liver- and Intestine-specific MTP-deficient (L,I-
Mttp/) Mice—To generate a mouse model of ABL, we con-
ditionally and simultaneously deleted the Mttp gene in the liver
and small intestine (L,I-Mttp/) of C57BL6Jmice.MTP activ-
ity, mRNA, and protein levels were reduced by 60% in the
livers and intestines of L,I-Mttp/mice compared with con-
trols (Fig. 2, A–E). Furthermore, apoB100 and apoB48 were
absent in the plasma of these mice (Fig. 2F). Although plasma
apoA1 levels were reduced (84%) in L,I-Mttp/ mice com-
pared with controls, Abca1 mRNA expression in the liver and
intestine was not affected (Fig. 2, G and H). Plasma concentra-
tions of triglyceride, phospholipid, cholesterol, and ceramide
were reduced by 90% in L,I-Mttp/ mice compared with
Mttpf/f control mice (Fig. 3A). Plasma sphingomyelin levels
were reduced by73% in theMTP-deficient mice, but levels of
hexosylceramide, lactosylceramide, dihydrosphingosine, and
dihydrosphingosine 1-phosphate (dihydrosphingosine-1P)
concentrationswere not. Plasma sphingosine concentrations in
L,I-Mttp/ mice were increased by 2-fold compared with
Mttpf/f mice. In contrast, plasma levels of sphingosine 1-phos-
phate (sphingosine-1P) were significantly decreased by 32% in
the same animals (Fig. 3A). The concentrations of all the major
ceramide species (supplemental Table S6) were significantly
reduced in the plasma of L,I-Mttp/ mice. Except for
decreases in levels of C22 and increases in C22:1 hexosylcer-
amide, other species were not significantly different (supple-
mental Table S7). The concentrations of C16 and C24:1 lacto-
sylceramide were significantly decreased in the plasma, but
levels of other species were not (supplemental Table S8). All
species of sphingomyelin were significantly reduced in L,I-
Mttp/ mice (supplemental Table S9). Thus, intestinal and
hepaticMTP deficiency reduces total plasma concentrations of
ceramide and sphingomyelin inmice. These changes were sim-
ilar to those seen in ABL subjects.
Hepatic lipid analysis revealed that tissue concentrations of
triglyceride and phospholipid were significantly reduced in the
L,I-Mttp/ mice compared with Mttpf/f mice, but those of
cholesterol, sphingomyelin, dihydrosphingosine, and sphingo-
sine 1-phosphate were not (Fig. 3B). In contrast, ceramide,
dihydroceramide, hexosylceramide, lactosylceramide, and
sphingosine levels were significantly increased in the livers of
FIGURE 1. Total plasma lipids in HE ABL and homozygous ABL subjects. A–C, plasma samples from HE (n 4) and HO (n 9) ABL were used to measure
triglyceride, phospholipid, and cholesterol using commercial kits. D, plasma (0.5 l) was separated on 4 –15% polyacrylamide gradient gels, transferred to
nitrocellulose, and blotted with goat anti-human apoB polyclonal antibodies (Academy Biomedical, catalog no. 20S-G2; 1:1,000 dilution). Blots were
then incubated with Alexa Fluor 633-labeled rabbit anti-goat antibodies (Invitrogen, catalog no. A-21082; 1:10,000 dilution) and visualized using a
phosphorimager (Storm 860, Molecular Dynamics, 635 nm). For apoAI, plasma (0.25 l) was separated on 10% polyacrylamide gels and blotted using goat
anti-human apoAI (Academy Bio-Medical Co., Inc., catalog no. 11S-G2, 1:2,000 dilution). Next, membranes were incubated with Alexa Fluor 633 donkey
anti-goat IgG (Life Technologies, Inc., catalog no. A-21082, 1:10,000 dilution) and visualized using a phosphorimager. The letters at the bottom correspond to
individual samples in the supplemental Tables S1–S5. E–M, various species of ceramide, sphingomyelin, hexosylceramide, and lactosylceramide in the plasma
of these subjects were measured using HPLC-MS/MS. Amounts of different species of sphingolipids were combined to obtain total concentrations. Individual
values are in supplemental Tables S1–S5. p values are after two-tailed Student’s t test. **, p 0.01; ***, p 0.001.
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L,I-Mttp/ mice. Significant hepatic accumulation of several
sphingolipids in L,I-Mttp/ mice suggest that liver MTP
might play an important role in the control of hepatic sphingo-
lipid metabolism.
Analyses of different species of ceramide indicated that livers
of L,I-Mttp/ mice accumulated significant amounts of C14,
C16, C18, C18:1, C24:1, and C26:1 ceramide, whereas amounts
of C20, C22, C24, C26 ceramide were reduced compared with
the levels in control animals (supplemental Table S6). Increases
in the concentrations of total hepatic hexosylceramide resulted
mainly from accretions of the C16, C18, and C24:1 species
despite a significant decrease in the C22 species (supplemental
Table S7). Significant increases in hepatic lactosylceramide lev-
els were due to accumulations of C16, C22, and C24:1 species
(supplemental Table S8). Although total hepatic sphingomy-
elin levels were not different in the livers of L,I-Mttp/ and
control mice, there were significant differences in the accre-
tions of different sphingomyelin species in L,I-Mttp/ mice;
tissue levels of C18 and C26:1 sphingomyelin were increased,
whereas those of the C20, C22, C22:1, C24, and C26 species
were significantly reduced (supplemental Table S9). These data
indicate that MTPmight play a significant role in the transport
of sphingolipids with C16, C18, C18:1, C24:1, and C26:1 fatty
acyl chains. The reasons for the observed decreases in the con-
centrations of the C22, C24, and C26 species of ceramide and
sphingomyelin species in the livers of L,I-Mttp/ mice are
unclear.
Intestinal lipid analysis showed increased levels of triglycer-
ide, phospholipid, and cholesterol, whereas sphingomyelin lev-
els were decreased in L,I-Mttp/ mice compared with con-
trols (Fig. 3C). No significant accretions of different species of
ceramide, dihydroceramide, hexosylceramide, lactosylcer-
amide, dihydrosphingosine, and sphingosine were observed in
the intestines of L,I-Mttp/ mice (supplemental Tables S6
–S9). Thus, glycerolipids and cholesterol accumulate selec-
tively in the intestines of L,I-Mttp/ mice, but sphingolipids
do not. These studies highlight tissue-specific roles of MTP in
the regulation of glycerolipids and sphingolipids. Furthermore,
these results suggest that intestinal MTP activity might con-
tribute significantly to plasma glycerolipid and cholesterol lev-
els, whereas MTP activity in the liver contributes to plasma
sphingolipid levels (see “Discussion”).
Analysis of fecal lipids revealed increased excretions of phos-
pholipid, cholesterol, ceramide, and sphingomyelin in L,I-
Mttp/ mice but not of glycosylceramide (Fig. 3D). Concen-
trations of other lipids were not different in L,I-Mttp/ mice
and Mttpf/f mice. Increases in fecal ceramide were correlated
with significant enhancements in C18, C20:1, and C24:1 spe-
cies, whereas those in sphingomyelin were due to increases in
C16 and C18:1 species (supplemental Tables S6–S9). Other
sphingolipid species were not significantly enhanced.
MTP Does Not Play a Role in Ceramide and Sphingomyelin
Synthesis but Is Required for Their Secretion—The above stud-
ies indicated that MTP deficiency significantly reduces plasma
ceramide and sphingomyelin in humans and mice. Therefore,
wewanted to find out howMTP regulates plasma ceramide and
sphingomyelin levels. We hypothesized that the low plasma
concentrations of ceramide observed during MTP deficiency
might be secondary to reduced synthesis of these lipids in the
liver. The liver expresses several ceramide synthases that prefer
different fatty acyl-CoA substrates (22, 42). The mouse liver
homogenates converted 90% of [3H]dihydrosphingosine to
dihydroceramide when incubated with lignoceroyl-CoA (Fig.
4A) consistent with this being the major hepatic ceramide syn-
thase activity (42). Fumonisin B1, an inhibitor of ceramide syn-
thesis (43), inhibited this process by75%, but an MTP inhib-
itor (MTPi; lomitapide) did not. Similarly,MTPi did not inhibit
synthesis of dihydroceramide in the presence of palmitoyl-
FIGURE 2. MTP and apoB levels in the liver, intestine, and plasma of L,I-Mttp/ mice. In L,I-Mttp/mice, the Mttp gene was conditionally deleted in the
liver and intestine as described under “Experimental Procedures.” A and B, liver and intestinal homogenates from Mttpf/f (n 5) and L,I-Mttp/ (n 5) mice
were used to measure MTP activity. C and D, MTP mRNA levels in the liver and intestine of MTP deficient and control mice. E, liver homogenates (25 g of
protein) were separated on a 10% polyacrylamide gel and transferred to a nitrocellulose membrane, probed with mouse anti-mouse MTP (BD Transduction
LaboratoriesTM, catalog no. 612022, 1:1,000 dilution) followed by Alexa Fluor 633-labeled goat anti-mouse IgG (Life Technologies, Inc., catalog no. A-21050,
1:10,000 dilution). For control, an identical blot was probed with anti-vinculin (Sigma, catalog no. V9131, 1:2,000 dilution). F, to detect apoA1 and apoB, plasma
(0.5l) was run on a 5–14% polyacrylamide gel and transferred to a nitrocellulose membrane. The membrane was cut in half. One-half was probed with rabbit
anti-mouse apoB (Meridian Life Science, catalog no. K23300R, 1:1,000 dilution) and then incubated with Alexa Fluor 633 goat anti-rabbit IgG (Life Technol-
ogies, Inc., catalog no. A-21070, 1:10,000 dilution). The other half was probed with goat anti-apoAI (Academy Bio-Medical Co., Inc., catalog no. 11S-G2, 1:2,000
dilution) followed by Alexa Fluor 633 donkey anti-goat IgG (Life Technologies, Inc., catalog no. A-21082, 1:10,000 dilution). Bands were visualized in a
phosphorimager. G and H, Abca1 mRNA levels in the liver and intestine of L,I-Mttp/ mice.
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FIGURE 3. Effect of hepatic and intestinal MTP deficiency on plasma and tissue lipids in mice. Chow-fed 8-week-old male Mttpf/f mice were injected
once intravenously with 109 pfu of either AAV-TBG-Luc (n  4) or AAV-TBG-Cre viruses (n  3) in 100 l of sterile PBS. Next, mice injected with
AAV-TBG-Luc were injected intraperitoneally with 200 l of corn oil for 3 alternate days. Mice injected with AAV-TBG-Cre were injected with 0.5 mg of
tamoxifen in 200l of corn oil for 3 alternate days to obtain L,I-Mttp/mice. Seven days after the last injection, mice were fasted for 16 h, and lipids were
measured in plasma (A), liver (B), and intestine (C). In a separate experiment, feces were collected over a period of 48 h fromMttpf/f (n 3) and L,I-Mttp/
(n 3) mice (D). Individual values for different sphingolipid species are in supplemental Tables S6 –S9. p values are after two-tailed Student’s t test. *, p
0.05; **, p  0.01; ***, p  0.001.
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CoA, and stearoyl-CoA (Fig. 4,B andC).Moreover, synthesis of
dihydroceramide in the presence of different fatty acyl-CoAs
was not affected byMTP deficiency in the livers of L,I-Mttp/
mice; however, the synthesis of dihydroceramide in Mttpf/f and
L,I-Mttp/mice was inhibited by fumonisin B1 (Fig. 4, D–F).
Thus, hepaticMTP deficiency does not affect dihydroceramide
synthesis in the tissues.
Next, we determined whether MTP deficiency affected di-
hydroceramide synthesis in intestinal homogenates. Murine
intestinal homogenates had lower conversion of dihydrosphin-
gosine to dihydroceramide compared with the liver consistent
with reduced expression of ceramide synthases in the intestine
(44), and this conversion was inhibited by fuminosin B (Fig.
4G). There were no significant differences between the synthe-
sis of dihydroceramide in Mttpf/f and L,I-Mttp/ intestinal
homogenates, indicating that MTP deficiency in the intestine
does not affect dihydroceramide synthesis.
To study the effect of MTPi on sphingomyelin synthesis in
intestinal and liver cells, murine primary enterocytes (Fig. 5A)
and Huh-7 cells (Fig. 5B) were labeled with NBD-ceramide. In
enterocytes, NBD-ceramide was converted to sphingomyelin
and glucosylceramide. SMSi inhibited the synthesis of sphingo-
myelin but not of glucosylceramide. Moreover, MTPi had no
effect on sphingomyelin and glucosylceramide syntheses. In
Huh-7 cells, NBD-ceramide was mainly converted to sphingo-
myelin. SMSi significantly reduced sphingomyelin synthesis;
however, MTPi had no effect. We then asked whether MTP
plays a role in sphingomyelin synthesis in liver homogenates
Synthesis of sphingomyelin in liver homogenates incubated
with NBD-ceramide was unaffected by MTPi (Fig. 5C) or Mttp
gene ablations (Fig. 5D). These studies show that MTP defi-
ciency has no effect on sphingomyelin synthesis.
To determine whether MTPi affects ceramide and sphingo-
myelin synthesis and secretion in cultured cells, we treated
FIGURE 4. Effect of MTP and ceramide synthase inhibition on the synthesis of ceramide. A–C, in vitro conversion of dihydrosphingosine to dihydrocer-
amide. Liver homogenates (250g of protein) from wild-type mice were incubated with [3H]dihydrosphingosine (0. 05Ci), dihydrosphingosine (15M), fatty
acid-free BSA (20 M), and lignoceroyl-CoA (50 M), palmitoyl-CoA (50 M), or stearoyl-CoA (50 M) in the presence or absence of MTP inhibitor (500 nM) or
fumonisin B1 (50 M) for 30 min at 37 °C. The reaction was stopped by adding 200 l of CHCl3/CH3OH (2:1, v/v). Lipids were extracted and subjected to TLC.
Radioactivity in the dihydrosphingosine and dihydroceramide bands was quantified.D–F, liver homogenates fromMttpf/f and L,I-Mttp/mice were incubated
with [3H]dihydrosphingosine (0.05Ci), dihydrosphingosine (15M), fatty acid-free BSA (20M) and different indicated fatty acyl-CoAs (50M) in the presence
and absence of fumonisin B1 (50M) or MTPi (500 nM) for 30 min at 37 °C. Lipids were extracted and separated on TLC.G, experiments were performed similarly
to D–F with intestinal homogenates from Mttpf/f and L,I-Mttp/mice. Bands were quantified with ImageJ. Significance was determined by one-way analysis
of variance followed by the Dunnett’s test to determine significance compared with control. p 0.05. Mean S.D., n 3.
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Huh-7 cells with and without MTPi. As a positive control, cells
were treated with fumonisin B1, a ceramide synthase inhibitor.
MTPi reduced apoB secretion by 88% with no effect on apoAI
secretion (Fig. 6, A and B). Fumonisin B1 had no effect on apoB
and apoAI secretion (Fig. 6, A and B). When Huh-7 cells were
labeled with [3H]dihydrosphingosine, a precursor for de novo
ceramide synthesis, radiolabeled lipids migrating with triglyc-
eride, ceramide, dihydrosphingosine, phosphatidylcholine, and
sphingomyelin markers were present in control cells at both 1
and 3 h (Fig. 6C). In the presence of fumonisin B1, synthesis of
radiolabeled ceramide and sphingomyelin was inhibited by
96 and 50% at 1 and 3 h, respectively, comparedwith controls,
but the synthesis of triglyceride and phosphatidylcholine was
not inhibited (Fig. 6C). MTPi had no effect on triglyceride, cer-
amide, phosphatidylcholine, and sphingomyelin synthesis.
These studies indicate that MTP does not play a role in glycer-
olipid and sphingolipid synthesis.
Next, we studied the effect of MTPi on the secretion of sph-
ingolipids.Media of control Huh-7 cells incubated with [3H]di-
hydrosphingosine for 16 h contained triglyceride, ceramide,
phosphatidylcholine, sphingomyelin, and other unidentified
lipids (Fig. 6D). MTPi inhibited the secretion of radiolabeled
triglyceride, ceramide, phosphatidylcholine, and sphingomy-
elin by 100, 90, 63, and 36%, respectively (Fig. 6D). Secretion of
triglyceride, ceramide, phosphatidylcholine, and sphingomy-
elin was reduced by 20, 67, 34, and 37%, respectively, in the
presence of fumonisin B1 (Fig. 6D). These studies show that
MTPi significantly reduces ceramide secretion, although it has
partial inhibitory effect on sphingomyelin secretion. Therefore,
ceramide secretion is more dependent on MTP activity than
sphingomyelin secretion, and it is likely that sphingomyelin is
transported to the plasma via multiple pathways.
MTP Transfers Ceramide and Sphingomyelin—We hypothe-
sized that MTP participates in ceramide and sphingomyelin
secretion by transferring these sphingolipids as it transfers glyc-
erolipids. Radiolabeled triolein, ceramide, and sphingomyelin
transfer increased with time from donor to acceptor vesicles in
the presence, but not in the absence, of purifiedMTP (Fig. 7A).
Transfer of these lipids also increased with increasing amounts
of purified MTP and was inhibited by MTPi (Fig. 7B). Transfer
of triolein appeared to saturate at0.5g ofMTP, whereas the
transfer of ceramide and sphingomyelin did not. It is likely that
transfer of triglyceride might involve high affinity, low capacity
binding sites, whereas sphingolipid transfer might involve low
affinity, high capacity binding. Despite these differences in lipid
transfer characteristics, MTPi inhibited the transfer of these
lipids with similar IC50 values (Fig. 7C). Thus, time- and pro-
tein-dependent transfer of ceramide and sphingomyelin by
MTP and inhibition of these transfer activities byMTPi suggest
that MTP transfers these sphingolipids.
Next, we evaluated the transfer of these lipids by cellular
MTP. Similar to purified MTP, mouse liver homogenates also
transferred these lipids, and their transfer was inhibited by
MTPi (Fig. 7D). Furthermore, the transfer of these lipids was
significantly reduced in MTP-deficient liver homogenates
compared with controls (Fig. 7E). These studies support the
FIGURE 5. Effect of MTP inhibition on the synthesis of sphingomyelin. A, enterocytes were isolated from Mttpf/f mice. Enterocytes were incubated with
NBD-ceramide (3.3 g/ml) and phosphatidylcholine (100 g/ml) in the presence or absence of lomitapide (MTPi, 500 nM), D609 inhibitor (SMSi, 500 M), or no
inhibitor (Inh) for 2 h. Lipids were extracted from the cells using isopropyl alcohol and separated on TLC. B, sphingomyelin synthesis was measured in Huh-7
cells as described above. C, in vitro synthesis of sphingomyelin. Liver homogenates (250 g of protein) from wild type mice were incubated in triplicate with
NBD-ceramide (1 M) for 30 min at 37 °C in the presence and absence of MTP inhibitor (500 nM), separated on TLC, and visualized with the phosphorimager. D,
in vitro synthesis of sphingomyelin was performed in liver homogenates obtained from Mttpf/f and L,I-Mttp/mice. Significance was determined by one-way
analysis of variance followed by the Dunnett’s test to determine significance of each group compared with untreated WT homogenate. p 0.05. Mean S.D.,
n 3.
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notion that MTP transfers ceramide and sphingomyelin as it
transfers triglycerides.
Discussion
MTP is essential for the secretion of triglycerides with B-lps,
but its role in the secretion of sphingolipids is unknown. Here,
we demonstrated the following: 1) plasma levels of ceramide
and sphingomyelin are significantly reduced in both ABL
patients and L,I-Mttp/ mice; 2) MTP is important for the
secretion of these sphingolipids but not for their synthesis; and
3) purified and cellularMTP transfers these sphingolipids from
donor to acceptor vesicles. Thus, it is likely that MTP assists in
the secretion of ceramide and sphingomyelin by transferring
them to B-lps in hepatocytes and enterocytes (Fig. 8A) and reg-
ulates their plasma levels.
Mechanisms Controlling Plasma Sphingolipids—Our studies
show that reductions in the biogenesis of B-lps secondary to
MTPdeficiency differentially affects plasma sphingolipids indi-
cating that some, but not all, sphingolipids are exclusively
secreted from the liver and intestine as part of B-lps. To deter-
mine whetherMTP and B-lp biogenesis are required for sphin-
golipid secretion, we quantified plasma sphingolipids in MTP-
deficient humans (ABL patients) and in mice deficient in liver
and intestinalMTP (L,I-Mttp/). In general, we observed sim-
ilar phenotypes in ABL patients andMTP-deficient mice; MTP
deficiency markedly reduced plasma ceramide and partial
reductions in sphingomyelin. In contrast to ceramide and
sphingomyelin, plasma levels of hexosylceramide, lactosylcer-
amides, dihydroceramide, dihydrosphingosine, dihydrosphin-
gosine-1P, and sphingosine were not affected by MTP defi-
ciency. The transport of sphingosine-1P may or may not be
dependent onMTP; sphingosine-1P was reduced in the plasma
of L,I-Mttp/ mice but not in the plasma of ABL patients.
Plasma levels of other quantified sphingolipids were not
affected by MTP deficiency, suggesting that they enter the
plasma compartment via alternative mechanisms, possibly
involvingHDL, albumin, or other unidentified proteins. Hence,
different complementarymechanisms exist for the transport of
various sphingolipids from the intestine and liver to the plasma
compartment. MTP specifically contributes to the majority of
plasma ceramide and some of sphingomyelin.
Attempts to understand how MTP regulates plasma cer-
amide and sphingomyelin revealed that MTP does not play a
role in their biosynthesis. No effect of MTP on sphingomyelin
synthesis suggests that MTP-mediated ceramide transport via
B-lps is not critical for its synthesis. These data also indicate
thatMTPdeficiency has no effect on ceramide transfer protein-
mediated transport of ceramide from the ER to Golgi that is
essential for sphingomyelin synthesis. Our studies, however,
show that MTP is important for the secretion of ceramide and
sphingomyelin. MTP is known to transfer triglyceride, choles-
terol ester, and phospholipid. We show for the first time that
MTP can also transfer ceramide and sphingomyelin between
vesicles. Therefore, it is possible that MTP could transfer these
lipids intracellularly to nascent B-lps or lipid droplets in the
lumen of the ER and Golgi and aid in their secretion (Fig. 8A).
The observation that MTP can also transfer ceramide and sph-
ingomyelin suggests that MTPmight be a general lipid transfer
protein. We speculate that it might recognize hydrophobic
motifs rather than specific molecular or structural determi-
nants and acts as a “general microsomal lipid transfer protein.”
Although MTP can transfer both ceramide and sphingomy-
elin, MTP deficiency has differential effects on their secretion.
One possible explanation is that sphingomyelin is both secreted
with B-lps and effluxed to HDL. Therefore, in the absence of
B-lps, sphingomyelin can still be effluxed toHDL.Alternatively,
this might be related to the amounts of MTP and sphingolipids
FIGURE 6. Effect of MTP and ceramide synthase inhibition on the synthesis and secretion of ceramide and sphingomyelin in Huh-7 cells.A andB,Huh-7
cells were incubated with 50M fumonisin B1 (FUM), 500 nM MTPi, or DMSO (CTRL) for 16 h. ApoB and apoA1 in media were measured using ELISA.C,Huh-7 cells
were treated with 50 M fumonisin B1 or 500 nM MTPi for 2 h in DMEM containing 10% FBS. Then, 0.5 Ci of [3H]dihydrosphingosine and 15 M dihydrosph-
ingosine were added to the media. Cells were collected at 1 or 3 h, and lipids were extracted, separated on TLC, and autoradiographed. Pure lipid markers run
in parallel were identified. Control cells received dimethyl sulfoxide (DMSO). D, Huh-7 cells were incubated with 0.5 Ci of [3H]dihydrosphingosine, 15 M
dihydrosphingosine, and 50 M fumonisin B1, 500 nM MTPi, or DMSO vehicle for 16 h. Lipids from the media were extracted and exposed to phosphorimager
screens. Images inC andD are each representative of two independent experiments performed in duplicate. This experiment was repeated in HepG2 cells with
similar results (data not shown). TG, triglyceride; Cer, ceramide; DHS, dihydrosphingosine; PC, phosphatidylcholine; SM, sphingomyelin.
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present in the ER and Golgi complex. MTP is mainly present in
the ER, and itmight efficiently transfer ceramide toB-lps.Much
lower amounts of MTP are present in the Golgi complex, a site
of sphingomyelin biosynthesis. Furthermore, sphingomyelin
levels are20-fold higher than those of ceramide. Therefore, it
is likely that MTP might be rate-limiting for the transfer of
sphingomyelin in the Golgi complex, and other mechanisms
might have evolved for its secretion.
The data presented here showed thatMTP does not contrib-
ute to plasma hexosylceramide and lactosylceramide levels.
Thereasonsforthisareunclear.Itispossiblethattheseglycosylcer-
amides are not transferred by MTP due to the presence of
hydrophilic sugar residues.Wewere unable to test this hypoth-
esis as the backgrounds of vesicles prepared with NBD-glyco-
sylceramides were too high to perform transfer assays. Another
possibility is that these sphingolipids are not available to MTP
FIGURE 7. MTP transfers ceramide and sphingomyelin. A, time course of lipid transfer by MTP. Different donor vesicles containing [3H]triolein,
[14C]ceramide, or [3H]sphingomyelin were incubated with phosphatidylcholine acceptor vesicles and 1 g of purified bovine MTP in triplicate for the
indicated times. Amounts of radiolabeled lipids transferred to acceptor vesicles were quantified in the absence (no MTP) or presence (with MTP) of
purified MTP. B, lipid transfer increases with the amounts of purified MTP. Different indicated amounts of purified bovine MTP were incubated for 2 h in
triplicate with donor vesicles containing [3H]triolein, [14C]ceramide, or [3H]sphingomyelins and acceptor vesicles. The reactions were carried out in the
absence (DMSO) or presence of 1 M MTP inhibitor (MTPi, lomitapide). C, inhibition of MTP lipid transfer activities by lomitapide. Purified bovine MTP (1
g) was incubated in triplicate with donor vesicles containing [3H]triolein, [14C]ceramide, or [3H]sphingomyelin and acceptor vesicles in the presence
of different indicated amounts of lomitapide. After 1 h, DE52 was added, and donor vesicles were separated by centrifugation. Amounts of radiolabel
transferred to acceptor vesicles were quantified and plotted. Non-linear regression analysis was used to calculate IC50 values. D, inhibition of cellular
lipid transfer activities by MTPi. Mouse liver homogenates (100 g of protein) were incubated in triplicate in the presence and absence of MTPi (1 M)
for 1 h. Lipids transferred to acceptor vesicles were quantified. E, lipid transfer activities in the livers of different knock-out mice. Liver homogenates (100
g of protein) from different mice were used to measure transfer of [3H]triolein, [14C]ceramide, and [3H]sphingomyelin as described under “Experimen-
tal Procedures.”
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for transfer. It is known that glycosylceramides are transferred
by FAPP2 within intracellular organelles (45); this transfer may
preclude the availability of these sphingolipids to MTP for
transfer to B-lps.
L,I-Mttp/ Mice Have Severe Hypolipidemia—Our data
show that acute concurrent ablation of MTP in the liver and
intestine results in a more severe hypolipidemia characterized
by very low levels of triglyceride, phospholipid, and cholesterol
than has been reported in liver-specific and intestine-specific
MTP-deficient mice (9–12). Significant reductions in plasma
cholesterol were unanticipated as the majority of cholesterol is
transported with HDL in mice, and reductions in B-lps should
not theoretically affect HDL cholesterol because Abca1 mRNA
levels did not change in MTP-ablated mice (Fig. 2, G and H).
However, we observed that apoA1 levels were in fact markedly
reduced. Because the hydrolysis of B-lps by lipoprotein lipase
contributes to HDL biogenesis, it is possible that the absence of
plasma B-lps contributes to lower production of HDL. Alterna-
tively, the phenotype may be unique to the acute gene ablation
model used in this study that perhaps does not allow compen-
satory changes inHDLbiogenesis to take place. Chronic studies
in these mice are required to fully understand the effects of
intestinal and hepatic MTP deficiency on HDL metabolism.
Role of Intestinal and Hepatic MTP in Tissue Lipid Homeos-
tasis—Our approach of comparing plasma, liver, and intestinal
levels of different glycerolipids, cholesterol, and sphingolipids
in MTP-deficient mice have provided new insights into the
mechanisms of tissue lipid homeostasis. Combined intestinal
and hepatic MTP deficiency significantly reduced plasma cho-
lesterol levels but did not affect hepatic intracellular cholesterol
levels. It is known that tissue cholesterol levels are tightly con-
trolled by additional mechanisms independent of their secre-
tion with lipoproteins.
Deficiencies of intestinal and liver MTP reduced plasma and
liver triglycerides and phospholipids while increasing their
concentrations in the intestine. Significant accumulations of
triglyceride and phospholipid in the intestines of these mouse
models suggest that intestinal transport might be a significant
determinant of triglyceride and phospholipidmetabolism. This
perhaps also indicates that the intestine may lack significant
mechanisms to control cellular levels of these lipids. Alterna-
tively, the main function of the intestine may be to either
secrete or store these lipids for later transport.
Combined intestinal and hepatic MTP deficiency results in
decreased accumulation of glycerolipids in the mouse liver,
which differs from observations in liver- or intestine-specific
MTP-deficient mice, as well as those seen in ABL subjects and
humans treated with MTP inhibitors (9, 11, 12, 46). In liver- or
intestine-specific MTP-deficient mice, triglycerides accumu-
late in the liver and intestine, respectively, suggesting that tis-
sue-specific MTP ablation is associated with tissue-specific
accretions of triglycerides. In humans, MTP deficiency is also
associatedwith accumulation of both intestinal and hepatic lip-
ids. It is possible that the phenotype observed in L,I-Mttp/ is
the early response due to acute ablation of the gene and that
long term deletions might result in significant accumulation of
lipids in both the liver and intestine.
In contrast to glycerolipids, sphingolipid accumulation in tis-
sues showed an opposite effect. Sphingolipids did not accumu-
late in the intestines of L,I-Mttp/ mice. Livers from L,I-
Mttp/ mice, however, had significantly higher amounts of
ceramide, hexosylceramide, lactosylceramide, and sphin-
gosines, but sphingomyelin levels did not change. We propose
that hepatocytes tightly control cellular ceramide and sphingo-
myelin levels (Fig. 8B). Inhibition of secretorymechanismsmay
enhance conversion of ceramide to other metabolites, such as
glycosylceramide, to avoid cellular toxicity and might explain
their accumulation in the liver of these mice. It is unclear why
plasma levels of glycosylceramides did not increase in these
mice despite increases in their hepatic levels. It is possible that
their secretion rates are limiting or they are stored for later
release. As discussed above, combined intestinal and hepatic
MTP deficiency had differential effects on tissue glycerolipids
and sphingolipids. L,I-Mttp/ mice accumulated significant
amounts of glycerolipids in the intestine and sphingolipids in
the liver. We speculate that in mice the intestine might be the
FIGURE 8. A, proposed model explaining the role of MTP in ceramide and sphingomyelin secretion. Ceramides are synthesized in the endoplasmic reticulum
(ER) and transported by ceramide transfer protein (CERT) and transport vesicles (Trans. Ves.) to the Golgi, where they are converted to sphingomyelin and
glycosphingolipids. We propose that MTP transfers ceramides to B-lps in the ER. These B-lps are then transported to the Golgi, where MTP transfers both
ceramide and sphingomyelin before secretion into the plasma. Sphingomyelin may also enter the plasma compartment via unknown mechanisms. Mecha-
nisms for secretion of hexosylceramides (HexCer) and lactosylceramide (LacCer) are unknown. B, simplified schematic representations of sphingolipid metab-
olism in MTP-deficient mice. Hepatocytes are shown to synthesize different sphingolipids starting from ceramide. In MTP-deficient mice, secretion of cer-
amides and sphingomyelin is severely curtailed. This results in the buildup of ceramides, hexosylceramides, lactosylceramide, and possibly other complex
sphingolipids (green arrows).Arrows coming out of the cell represent secretion of ceramides and sphingomyelin involving an MTP-dependent process. The red
cylinder represents a blood vessel.
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major organ controlling glycerolipid metabolism, whereas the
liver might be the major organ modulating sphingolipid home-
ostasis. It is likely that intestinal lipoproteins (chylomicrons)
transport glycerolipids to the liver, and the liver re-circulates
them via VLDL production. In the absence ofMTP, these lipids
mainly accumulate in the intestine. In contrast, ceramide and
glycosylceramide in the liver of L,I-Mttp/ mice may simply
accumulate because they are not secreted with lipoproteins.
More studies are needed to knowwhydifferent ceramides accu-
mulate in the liver but not in the intestine.
Cholesterol and phospholipids were significantly increased
in the feces of L,I-Mttp/ mice compared with control, pre-
sumably due to reduced absorption by intestinal cells. Similarly,
ceramide and sphingomyelin levels were elevated in the feces of
L,I-Mttp/mice compared with control.We hypothesize that
the increase in sphingomyelin and ceramide in the feces of L,I-
Mttp/ mice is due to reduced hydrolysis and absorption of
sphingomyelin and ceramide. Alternatively, the increase in
sphingomyelin and ceramide excretionmay be due to increased
shedding of intestinal epithelial cells.
Individual ablation of the Mttp gene in the liver or intestine
may yield different results than those seen in L,I-Mttp/mice.
We expect to see a decrease in plasma ceramide and sphingo-
myelin in liver-specific MTP knock-out mice (L-Mttp/)
compared with WT mice. We speculate that L-Mttp/ mice
would still accumulate sphingolipids (ceramide, lactosylcer-
amide, and hexosylceramide) in their livers. However, it is pos-
sible that lactosylceramide and hexosylceramidemay not accu-
mulate in their livers because liver-specific MTP deficiency
doesnothaveadramaticeffectonHDL.Therefore,ifglycosylcer-
amide enters the plasma compartmentwithHDL andHDLbio-
genesis is normal, plasma lactosylceramides and hexosylcer-
amidesmaybe similar toWTmice. Because the intestinedoesnot
appear tobe themain regulatorofplasmasphingolipids, theremay
be onlymoderate decreases in plasma ceramide and sphingomy-
elin in intestine-specific MTP-deficient (I-Mttp/) mice.
Analysis of plasma, hepatic, and intestinal sphingolipids in liv-
er- and intestine-specific MTP knock-out mice may lend
insight into the relative contribution of these two tissues to
plasma sphingolipids.
Similarities and Differences in Plasma Concentrations of Sph-
ingolipids in Humans and Mice—Comparison of plasma lipid
concentrations between humans and mice in general indicates
that plasma glycerolipids and sterols are 50% less in mice
(Figs. 1 and 3A). Plasma ceramide and sphingomyelin levels in
mice are25% of those seen humans. Plasma lactosylceramide
levels are exceptionally low in mice. Surprisingly, plasma he-
xosylceramide, dihydrosphingosine-1P and sphingosine-1P
levels are similar in humans and mice. Although low in both
species compared with other sphingolipids, dihydrosphin-
gosine levels are higher in mice. The reasons and physiological
consequences of different levels of plasma lipids in the two spe-
cies are not clear. However, our studies indicate that molecular
mechanisms contributing to the modulation of plasma cer-
amide and sphingomyelin in both the species might be similar.
There were significant differences in the reduction of plasma
sphingomyelin in ABL patients and in L,I-Mttp/ mice. The
sphingomyelin levels were significantly lower in L,I-Mttp/
mice than in ABL subjects. Because L,I-Mttp/ mice have
markedly reduced apoA1 levels compared with ABL patients,
this may cause a greater decrease in plasma sphingomyelin in
mice compared with humans.
In short, these studies provide evidence for the existence of
several mechanisms for the transport of sphingolipids and the
involvement ofMTP in the transport of ceramide and sphingo-
myelin. MTP appears to be the major determinant of plasma
ceramide. In contrast, it partially contributes to plasma sphin-
gomyelinandisnotinvolvedinthecontrolofplasmaglycosylcer-
amides. MTP may regulate plasma ceramide and sphingomy-
elin by transferring these lipids to B-lps and facilitating their
secretion. Further investigations may unravel novel mecha-
nisms involved in the secretion and transport of various
sphingolipids.
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